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Introduction {#sec1}
============

Coronaviruses can cause major outbreaks with fatal pneumonia, e.g., the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 with a fatality rate of around 10% ([@bib19]) or the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 with a fatality rate of 35% ([@bib8]). In 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the disease COVID-19 and led to a pandemic ([@bib33]). The common symptoms of COVID-19 include fever, cough, shortness of breath, and dyspnea. A more severe progression of the COVID-19 disease may lead to pneumonia and severe acute respiratory syndromes. Unfortunately, there are no specific drugs or vaccines approved for the treatment of COVID-19 yet ([@bib15]).

Traditionally, *de novo* drug design and drug repurposing are the common strategies scientists use to combat viral diseases. However, designing a new drug is very time consuming and needs extensive testing before clinical use in humans. In contrast, the repurposing of approved drugs or drugs in clinical trials is more promising, in particular as these have already been tested for side effects, toxicity, bioavailability, etc. At the moment, there is a huge amount of data from studies that analyze potential drugs based on computer simulations, *in vitro* studies, case studies, or clinical trials. However, none of the proposed treatments for COVID-19 have been proven to be clinically effective yet.

Potential drugs can target viral proteins or human proteins. At the time of writing, the most important viral target molecules that have been investigated for drug repurposing are SARS-CoV-2 spike protein, main protease (3CLpro, Mpro), papain-like proteinase (PLpro), and RNA-dependent RNA polymerase (RdRp) ([@bib22]; [@bib31]), whereas the main targets on the human cell membrane are angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) ([@bib3]). Besides these targets, several other candidates have been investigated as potential targets. Such investigations occurred on both viral and human sides, e.g., the methyltransferase and furin, respectively ([@bib4]; [@bib18]). Also, several potential drugs were announced at the beginning of the pandemic, which later proved to be insufficiently effective or even harmful to patients, such as hydroxychloroquine or chloroquine phosphate. For instance, [@bib10] reported a significant decrease in viral load in patients treated with hydroxychloroquine compared with controls. However, others have shown that these potential drugs can have severe side effects such as cardiac toxicity and also increased mortality ([@bib20]). Nevertheless, some of those studies showing higher mortality were later retracted because of a lack of transparency concerning the data ([@bib21]). Other potential drug candidates, such as a combination of lopinavir with ritonavir (also known as Kaletra), were first considered promising candidates ([@bib17]) but later shown to be ineffective for SARS-CoV-2 ([@bib5]). Nevertheless, many new drug candidates have been proposed by using different computational approaches, which address different viral and human targets ([@bib16]; [@bib23]).

The SARS-CoV-2 virus uses the human receptor ACE2 for cell entry, which is also used by SARS ([@bib11]; [@bib26]; [@bib28]; [@bib32]). It is expressed as a membrane-bound protein in the lungs, heart, kidneys, stomach, spleen, intestine, bone marrow, kidney, liver, brain, testis, and placenta ([@bib24]; [@bib9]; [@bib25]). Moreover, [@bib14] showed that SARS-CoV-2 depends on TMPRSS2, which therefore can serve as a target in therapy as well. TMPRSS2 primes the spike protein of SARS-Cov-2 to enable cell entry on ACE2. The authors further suggested that ACE2 binding to the spike protein might have a higher affinity compared with SARS. This may explain the infection of the upper respiratory system by SARS-CoV-2, which has not been observed in SARS, because in the upper respiratory system less ACE2 is expressed.

Structurally, each virion is approximately 50--200 nm in diameter ([@bib6]). Like other coronaviruses, SARS-CoV-2 has four structural polyproteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome, whereas the S, E, and M proteins together are part of the viral envelope. Upon successful attachment of the virus to the membrane of the host cell via the spike protein, the virus fuses with the membrane ([@bib27]; [@bib14]). Next, the endosome sees a drop in pH and the genomic RNAss(+) is released into the cell\'s cytoplasm ([@bib29]). As shown in [Figure 1](#fig1){ref-type="fig"}, upon uncoating and release of the RNA + sense viral genome in the cytoplasm, the host ribosome translates the viral RNA replicase or the viral RNA-dependent RNA polymerase (RdRp) ([@bib1]; [@bib30]). This triggers proteolysis using the main protease of SARS-CoV-2 (also named 3CLpro) and the papain-like proteinase (PLpro) and enables the replicate-transcriptase complex to transcript subgenomic RNAs(+) ([@bib2]; [@bib7]). Pre-genomic RNAss(−) are replicated into genomic RNAss(+), whereas the former translation of subgenomic RNA(+) results in the aforementioned polyproteins. Essentially, the virus RNA uses the host cell to create new viral RNA genomes and to assemble new viral particles. These are the aforementioned S, E, M, and N structural proteins. They transit to the endoplasmic reticulum and are recruited for the assembly and building of new virions into the Golgi apparatus and burgeon out of the apparatus to then form mature virions ([@bib12]). The N protein allows the viral genome to be extremely tightly packed into future viral capsids. In the end, new virions are released out of the host cell to infiltrate other cells in the host organism ([@bib13]). A simplified illustration of the replication cycle of the SARS-CoV-2 virus is shown in [Figure 1](#fig1){ref-type="fig"}.Figure 1Overview of the Replication Cycle of SARS-CoV2 Inside a Human CellThe main targets that are investigated for drug repurposing are reported.Figure 2Depiction of All Processing Steps within the CORDITE Workflow.(A) Literature aggregation.(B) database curation.(C) web interface.

The knowledge from the life cycle of the SARS-CoV-2 virus offers a great potential to find suitable drugs for the already known targets. To combine the large amounts of current knowledge, we centralize the aggregated information from published articles and preprints about potential drugs, targets, and their interactions into CORDITE (CORona Drug InTEractions database), which includes a web interface and an application programming interface (API).

Results {#sec2}
=======

CORDITE integrates many functionalities to enable users to access, sort, and download relevant data to conduct meta-analyses, to design new clinical trials, or even to conduct a curated literature search. CORDITE automatically incorporates publications from PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), bioRxiv (<https://www.biorxiv.org/>), chemRxiv (<https://www.chemrxiv.org/>), and medRxiv (<https://www.medrxiv.org/>) that report information on computational, *in vitro*, or case studies on potential drugs for COVID-19 (see [Figure 2](#fig2){ref-type="fig"}). Besides original research, we also included reviews and comments in the database. The information from the articles and preprints are manually curated by moderators and can be accessed via the web interface or the open API. Users can directly access the publications, interactions, drugs, targets, and clinical trials. The interactions and the effectiveness of certain drugs are also shown as positive/negative results in a transparent way. Thus, the user can easily see the contradictory results of different studies and can take these into account for, e.g., meta-analyses. This access may offer easier integration for future software or apps that may need curated data.

Moreover, we include registered clinical trials from the National Institutes of Health (<https://clinicaltrials.gov/>) for COVID-19. The CORDITE database is updated through manual curation. The current summary for interactions, drugs, etc., is reported in [Table 1](#tbl1){ref-type="table"}. An introductory video for the use of CORDITE can be found on the website.Table 1Summary Table of all Entry Types at Date of SubmissionTypeNumbersInteractions849Targets25Drugs639Publications324Clinical trials247

Discussion {#sec3}
==========

CORDITE provides an easy-to-use web interface and also access to an easy-to-use API that allows a wide use for other software and applications, e.g., for meta-analysis, design of new clinical studies, or simple literature search. CORDITE is currently the largest curated database for drug interactions for SARS-CoV-2, and therefore it offers the opportunity to accelerate research in the knowledge domains of virology and drug design. Because of the popularity and impact of the CORDITE website and database, we plan to continue hosting and managing CORDITE throughout the COVID-19 pandemic. Moreover, we will continuously improve the website and database to establish a standard tool for future diseases. We believe our efforts are essential to help researchers and clinicians to get an overview of existing studies and to accelerate the global search for new treatments.

Limitations of the Study {#sec3.1}
------------------------

CORDITE aggregates available knowledge on drugs for COVID-19; however, in particular the preprints have not been peer reviewed. Thus, CORDITE cannot guarantee the reliability of the studies and their results, in particular the effectiveness of the drugs.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Dominik Heider (<dominik.heider@uni-marburg.de>).

### Materials Availability {#sec3.2.2}

This study did not generate new unique data.

### Data and Code Availability {#sec3.2.3}

This study did not generate data. The curated data can be accessed freely via the API.

Availability: CORDITE is available at [https://cordite.mathematik.uni-marburg.de](http://cordite.mathematik.uni-marburg.de){#intref0040}.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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